Standard BioTools Inc. Impairment of Intangible Assets, Finite-lived
Standard BioTools Inc. (LAB) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2025-03-11
- Standard BioTools Inc. impairment of intangible assets, finite-lived for the quarter ending 2024-12-31 was $0.00.
- Standard BioTools Inc. impairment of intangible assets, finite-lived for the quarter ending 2024-09-30 was $0.00.
- Standard BioTools Inc. impairment of intangible assets, finite-lived for the quarter ending 2024-06-30 was $0.00.
- Standard BioTools Inc. impairment of intangible assets, finite-lived for the quarter ending 2024-03-31 was $0.00.
- Standard BioTools Inc. impairment of intangible assets, finite-lived for fiscal 2024 was $0.00.
- Standard BioTools Inc. impairment of intangible assets, finite-lived for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Standard BioTools Inc. impairment of intangible assets, finite-lived for fiscal 2022 was $3.53M.
- Standard BioTools Inc. impairment of intangible assets, finite-lived for fiscal 2021 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $3.53M 10-K · filed 2025-03-11 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.53M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $3.53M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $0.00 derived: sum of 2 quarters · filed 2023-03-14 | $0.00 10-K · filed 2023-03-14 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-08 | |||
| 2019-12-31 | $400.00K 10-K · filed 2021-02-25 | $443.00K 10-K · filed 2022-03-08 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |